Aural Analytics Gets FDA Approval
The U.S. Food and Drug Administration (FDA) has registered Aural Analytics' Speech Vitals product as a computerized cognitive assessment aid, a class II software medical device (SaMD).
Aural Analytics built a quality management system (QMS) to meet FDA and other regulatory requirements. This QMS will allow Speech Vitals to become a routine vital sign in clinic and at home.
"Human speech relies on coordinating complex neural activity, including cognitive and motor functions," said Judy Smythe, CEO of Aural Analytics, in a statement. "As cognitive disease develops, subtle changes in speech occur, which can be precisely detected using our powerful speech analytics. Speech Vitals has tremendous potential and value in a clinical setting, aiding providers in early detection of cognitive conditions that can be challenging to distinguish, especially in early stages. Our FDA registration ensures a high standard in disease diagnosis through our validated speech metrics."
Speech Vitals collects just a few minutes of speech samples from patients via app-based tasks that measure speaking rate, articulatory precision, word search time, and other factors.
Aural Analytics' speech analytics will help assess concussions following in-game injuries.
Aural Analytics' Speech Vitals technology will be used for a study to track the progression of Lou Gehrig's disease in patients.
Medidata's Sensor Cloud Network will include Aural Analytics' Speech Vitals platform.
The NIH grant will support Aural Analytics work with Speech Vitals to deliver clinical-grade speech analytics.
Aural's Speech Vitals technology will support Koneksa digital biomarker technology during clinical trials of pharmaceuticals.
Aural Analytics and Healint partner on integration of speech analytics into Healint's clinical trials and consumer applications.